Dr. Ransom obtained a B.A. in Biology and Psychology from the University of Delaware, and then earned a Ph.D. in Physiology from the UT Southwestern Medical Center. He pursued post-doctoral studies in Immunology at National Jewish Health, where he and co-founder, Dr. Bill Golde, first met and compared notes on the importance of having reliable tools to be able to generate accurate biological results. He continued to study Immunology at the DNAX Research Institute, followed by an engaging period in pharmaceutical discovery and development at Syntex Research. His career then continued as Director, Vice President and CSO at several biotechnology companies (Cadus, Axiom, Novasite, Cytori, Advanced Molecular Design, 82 Biosciences), some of which he co-founded. Most recently he was the VP of R&D and Head of Emerging Technologies at BioLegend, Inc, a successful biological reagents company. Currently he is co-founder and Chief Scientific Officer of Vivreon Biosciences, LLC. He is currently a Board member and SAB member for Stabilux Biosciences, and has recently co-authored clinical research papers that report on the safety and efficacy of a human bone marrow mesenchymal stem cell derived extracellular vesicle preparation currently in late clinical development for Direct Biologics.